Stock TGTX TG THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
16.3 USD -3.49% Intraday chart for TG Therapeutics, Inc. -2.45% -4.57%
May. 01 Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts MT
May. 01 Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
AQ
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
AQ
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
AQ
TG Therapeutics: Q1 Earnings Snapshot
AQ
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
AQ
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
AQ
TG Therapeutics Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
AQ
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
AQ
TG Therapeutics: Q4 Earnings Snapshot
AQ
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
AQ
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
AQ
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
AQ
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
AQ
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TGTX Stock
  4. News TG Therapeutics, Inc.
  5. Press Releases